QC
ONCY

Quent Capital’s Oncolytics Biotech ONCY Stock Holding History

Quent Capital’s Portfolio ONCY Stock Details ONCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-474
Closed -$1K – 1353
2022
Q3 		$1K Hold
474
– – ﹤0.01% 1170
2022
Q2 		$0 Hold
474
– – ﹤0.01% 1271
2022
Q1 		$1K Buy
+474
New +$795 ﹤0.01% 1212

Other funds holding ONCY

IAIM
International Assets Investment Management Orlando, Florida $1.67B AUM 28.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CIBC World Market
CIBC World Market Toronto, Ontario, Canada $61.3B AUM 39.33% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Quent Capital's ONCY Position: Q4 2022 in Review

Quent Capital sold out of Oncolytics Biotech (ONCY) in Q4 2022, closing a stake of 474 shares — an estimated $1K sold.

Quent Capital first reported a position in ONCY in Q1 2022 and held it in 3 quarters. The position peaked at $1K in Q3 2022. 35 funds tracked by Wall St. Rank hold ONCY as of Q4 2022.

  • Quent Capital reported no remaining Oncolytics Biotech position as of Q4 2022 after selling out during the quarter.
  • Quent Capital sold 474 Oncolytics Biotech shares in Q4 2022, an estimated $1K.
  • Quent Capital first reported a position in Oncolytics Biotech in Q1 2022 and held it in 3 quarters.
  • Quent Capital's Oncolytics Biotech position peaked at $1K in Q3 2022.
  • 35 funds tracked by Wall St. Rank held Oncolytics Biotech as of Q4 2022.

Based on Quent Capital's 13F filing for Q4 2022, filed 19 Jan 2023.